Gene Therapies for Primary Immune Deficiencies

Area of Science:

• Immunology and Genetics
• Biotechnology and Gene Therapy

Background:

• Primary Immune Deficiencies (PIDs) are a group of genetic disorders affecting the immune system.
• Gene therapy using autologous hematopoietic stem cell transplantation (HSCT) offers a potential treatment by correcting the underlying genetic defect.
• Early gene therapy attempts for PIDs faced challenges with genotoxicity due to integrating retroviral vectors.

Purpose of the Study:

• To review the evolution and current status of gene therapy for Primary Immune Deficiencies.
• To highlight the safety and efficacy improvements achieved with newer vector technologies.
• To compare gene therapy outcomes with allogeneic HSCT.

Main Methods:

• Utilized self-inactivating (SIN) lentiviral vectors for gene delivery, enhancing safety profiles.
• Administered autologous hematopoietic stem cells with corrected or edited genes.
• Reviewed clinical data from gene therapy trials for various PIDs.

Main Results:

• SIN lentiviral vectors demonstrate excellent safety, with no reported clinically significant genotoxicity.
• Gene therapy has shown successful clinical efficacy in treating multiple PIDs, including SCID, Wiskott-Aldrich Syndrome, and CGD.
• Gene therapy outcomes are comparable or superior to allogeneic HSCT in terms of efficacy and safety.

Conclusions:

• Gene therapy has significantly advanced as a safe and effective treatment for PIDs.
• Modern gene therapy approaches, particularly with SIN vectors, offer a promising alternative to allogeneic HSCT.
• Continued methodological improvements are expected to expand gene therapy's application to a wider range of PIDs.